From the Journals

GIMEMA ALL2820: Chemotherapy-Free Regimen Studied in Front-Line Setting

As front-line therapy, a chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed standard treatment ...

Share

The GIMEMA ALL2820 trial revealed that a chemotherapy-free regimen using ponatinib and blinatumomab significantly improves treatment outcomes for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) compared to standard chemotherapy with imatinib. The study demonstrated greater event-free survival, remission, and measurable residual disease response, suggesting this approach should become the new standard of care. Researchers emphasized the potential benefits of reduced secondary malignancies, especially for younger patients. The trial's results highlight a paradigm shift in treatment methodologies.

Original Source(s)

GIMEMA ALL2820: Chemotherapy-Free Regimen Studied in Front-Line Setting

As front-line therapy, a chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed standard treatment ...

  • by Caroline Helwick

  • March 4, 2026

  • 8 min

Related Content

Fellowship Training That Goes Where You Go

As Chief Fellow Giuliana Berardi, MD, a third-year Hematology/Oncology Fellow at Fox Chase Cancer Center, reflected on her medical training, she noted the steep learning curve that accompanied each new level of medical training.

  • by

  • February 16, 2026

  • 2 min
Delivering Big Ideas from ASH 2025

At Fox Chase Cancer Center and Temple University Hospital, it’s “in the blood” of our residents and Fellows to develop innovative scientific ideas that significantly affect the way blood diseases are diagnosed and treated. Here is the latest from ASH 2025:

  • by

  • February 17, 2026

  • 1 min
Bone Marrow Transplant: How Keck Medicine of USC Is Excelling in Survival Outcomes

Preet M. Chaudhary, MD, PhD, discusses the repeat ranking of the USC Norris Blood and Marrow Transplant and Cell Therapy Program as one of the nation’s elite allogeneic transplant programs with the highest survival outcomes.

  • by

  • February 13, 2026

  • 12 min